New Data from Phase 3 Teprotumumab Trial Shows Dramatic Reduction in Proptosis, or Eye Bulging, the Main Cause of Morbidity in Active Thyroid Eye Disease | oneGRAVESvoice

welcome to oneGRAVESvoice

- a positively charged Graves' disease and thyroid eye disease community.
  • join today!

New Data from Phase 3 Teprotumumab Trial Shows Dramatic Reduction in Proptosis, or Eye Bulging, the Main Cause of Morbidity in Active Thyroid Eye Disease


Horizon Pharma plc today announced that new data from the Phase 3 confirmatory clinical trial (OPTIC) evaluating the investigational medicine teprotumumab for the treatment of active thyroid eye disease (TED) were presented as part of a late-breaking oral presentation at the 2019 American Association of Clinical Endocrinologists (AACE) Scientific and Clinical Congress in Los Angeles. In addition to primary endpoint data previously announced on Feb. 28, 2019, the presentation includes new data from two secondary endpoints that show a dramatic reduction in proptosis (eye bulging) and a substantial improvement in overall response rate in patients treated with teprotumumab compared with placebo. 

These data demonstrate the potential for teprotumumab as a treatment for Active TED, which currently has no U.S. Food and Drug Administration (FDA) approved treatments. Teprotumumab is an investigational medicine and its safety and efficacy have not been established.

New Data From Phase 3 Teprotumumab Trial Shows Dramatic Reduction In Proptosis, Or Eye Bulging, The Main Cause Of Morbidity In Active Thyroid Eye Disease
Font Resize

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close